CoChat

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Open access
Wang, Haolan, Guo, Ming, Wei, Hudie, Chen, Yongheng · 2023 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 586 of the 586 references it cites were found in a registry or an index; 8 of the 520 sources its claims cite were checked for support.

Abstract

The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has been a major focus of oncology research. The p53 protein is a transcription factor that can activate the expression of multiple target genes and plays critical roles in regulating cell cycle, apoptosis, and genomic stability, and is widely regarded as the “guardian of the genome”. Accumulating evidence has shown that p53 also regulates cell metabolism, ferroptosis, tumor microenvironment, autophagy and so on, all of which contribute to tumor suppression. Mutations in TP53 not only impair its tumor suppressor function, but also confer oncogenic properties to p53 mutants. Since p53 is mutated and inactivated in most malignant tumors, it has been a very attractive target for developing new anti-cancer drugs. However, until recently, p53 was considered an “undruggable” target and little progress has been made with p53-targeted therapies. Here, we provide a systematic review of the diverse molecular mechanisms of the p53 signaling pathway and how TP53 mutations impact tumor progression. We also discuss key structural features of the p53 protein and its inactivation by oncogenic mutations. In addition, we review the efforts that have been made in p53-targeted therapies, and discuss the challenges that have been encountered in clinical development.

Overview

CoChat Summary

TL;DR

This review synthesizes p53 pathway biology, TP53 mutation mechanisms, p53 structural features, and therapeutic strategies targeting wild-type and mutant p53. It concludes that despite extensive drug development, no p53-targeted therapy is approved, with major challenges in reactivating mutant p53 and targeting its structural domains.

Key findings

  • TP53 is the most frequently altered gene in human cancers; 42% of cases carry TP53 mutations, with tissue-specific frequencies such as ovary 47.27%, colon and rectum 44.55%, lung 40.8%, esophageal carcinoma 93.77%, and small cell lung cancer 79.06%.
  • p53 is a 393-amino-acid transcription factor with domains TAD (1–61), PRD (64–92), DBD (96–292), TET (324–356), and CTD (364–393); more than 40% of p53 is intrinsically disordered. Hotspot missense mutations in the DBD (R175, G245, R249, R282, R248, R273) cause loss-of-function, dominant-negative, and gain-of-function effects.
  • p53 regulates classical pathways (cell cycle, apoptosis, genomic stability) and non-classical pathways (metabolism, ferroptosis, tumor microenvironment, autophagy, stem cell self-renewal); mutant p53 promotes metastasis, drug resistance, and immune evasion.
  • Therapies in development include MDM2/MDMX inhibitors (RG7112 Kd = 2.9 nM; RG7388 Kd = 0.15 nM; AMG232 Kd = 0.045 nM; ALRN-6924 MDM2 Kd = 10.9 nM and MDMX Kd = 57 nM) and mutant p53 rescue compounds (APR-246 plus azacitidine phase III complete remission 33.3% vs 22.4% with azacitidine alone, not statistically significant; ATO increased thermostability by 0.9–6.5 °C and transcriptional activity up to 44-fold; PC14586 caused complete tumor regression in 80% of mice). No p53-targeted drugs are approved.

Methods

  • Design: systematic review of p53 signaling, TP53 mutations, p53 structures, and p53-targeted therapies.
  • Data: published literature, structural studies and PDB entries, cancer genomic databases (COSMIC, cBioPortal, TCGA), and clinical trial registries with NCT identifiers and status.
  • Analysis: narrative synthesis with tables summarizing MDM2/X inhibitors, mutant p53 rescue compounds, and second-site suppressor mutations; no meta-analysis or formal quantitative pooling is described.

Limitations

  • Stated: lack of an established mechanism for p53 reactivation, lack of drug-binding pockets except Y220C, resistance to TP53 mutations, off-target effects, and possible toxicity from p53 accumulation in normal tissues; full-length p53 structures and some mutant structures remain unavailable; AlphaFold2 cannot correctly predict the structural impact of missense mutations.
  • Stated: many mutant p53 rescue drugs have p53-independent effects or irreproducible mechanisms, and no p53-targeted drugs are approved.
  • Evident: as a narrative review, no systematic search strategy, inclusion criteria, or risk-of-bias/quality assessment is described; clinical trial data are summarized from registries and may be incomplete or heterogeneous.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01347-1

Cites

586 of 586 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Timeline of some major advances in p53 research
Fig. 1 Timeline of some major advances in p53 researchCC BY · PubMed Central
Fig. 2 The p53 pathway. Under normal conditions, p53 protein levels are tightly regulated by MDM2/X, which together ubiquitinate p53, leading to proteasomal degradation of p53. Under stress conditions, p53 is activated and stabilized by post-translational modifications. Stabilized p53 forms tetramers in the nucleus, binds to target DNA, regulates gene transcription, and controls many different biological processes. ALDH4 aldehyde dehydrogenase family 4 member A1, ALOX12 arachidonate-12-lipoxygenase, AMPK 5′-AMP-activated protein kinase, APAF1 apoptotic protease-activating factor 1, Atgs autophagy-related genes, ATM ataxia-telangiectasia mutated proteins, ATR ataxia telangiectasia and Rad3-related, BAX apoptosis regulator BAX, CDC cell division cycle, CDK cyclin-dependent kinase, COX-2 cyclooxygenase-2 (also known as PTGS2), CPT1C carnitine palmitoyltransferase 1C, Cyt C Cytochrome C, DDB2 damage specific DNA binding protein 1, DPP4 dipeptidyl peptidase-4, DRAM damage regulated autophagy modulator 2, FANCC fanconi anemia group C protein, FDXR ferredoxin reductase, GADD45 growth arrest and DNA damage-inducible 45, GLS2 glutaminase 2, GLUT glucose transporter type, GPX glutathione peroxidase, G6PDH glucose‑6‑phosphate (G-6‑P) dehydrogenase, HMGB1 high-mobility group box-1, MCD malonyl-coenzyme A decarboxylase, mTOR mammalian target of rapamycin, NOXA superoxide-generating NADPH oxidase, PAI1 plasminogen activator inhibitor 1, PANK1 pantothenate kinase 1, PDK PDH kinase, PIGs p53-induced gene, PML promyelocytic leukemia protein, PRL3 phosphatase of regenerating liver-3, PTPRV protein tyrosine phosphatase receptor type V, PUMA Bcl-2-binding component 3, ROS reactive oxygen species, RRM2 ribonucleoside-diphosphate reductase subunit M2, SAT1 spermine N1-acetyltransferase 1, SLC7A11 solute carrier family7 member11, TFR1 transferrin receptor 1, TIGAR TP53-induced glycolysis and apoptosis regulator, TP53INP1 tumor protein p53 inducible nuclear protein 1, XPC xeroderma pigmentosum group C protein, YAP1 yes-associated protein 1
Fig. 2 The p53 pathway. Under normal conditions, p53 protein levels are tightly regulated by MDM2/X, which together ubiquitinate p53, leading to proteasomal degradation of p53. Under stress conditions, p53 is activated and stabilized by post-translational modifications. Stabilized p53 forms tetramers in the nucleus, binds to target DNA, regulates gene transcription, and controls many different biological processes. ALDH4 aldehyde dehydrogenase family 4 member A1, ALOX12 arachidonate-12-lipoxygenase, AMPK 5′-AMP-activated protein kinase, APAF1 apoptotic protease-activating factor 1, Atgs autophagy-related genes, ATM ataxia-telangiectasia mutated proteins, ATR ataxia telangiectasia and Rad3-related, BAX apoptosis regulator BAX, CDC cell division cycle, CDK cyclin-dependent kinase, COX-2 cyclooxygenase-2 (also known as PTGS2), CPT1C carnitine palmitoyltransferase 1C, Cyt C Cytochrome C, DDB2 damage specific DNA binding protein 1, DPP4 dipeptidyl peptidase-4, DRAM damage regulated autophagy modulator 2, FANCC fanconi anemia group C protein, FDXR ferredoxin reductase, GADD45 growth arrest and DNA damage-inducible 45, GLS2 glutaminase 2, GLUT glucose transporter type, GPX glutathione peroxidase, G6PDH glucose‑6‑phosphate (G-6‑P) dehydrogenase, HMGB1 high-mobility group box-1, MCD malonyl-coenzyme A decarboxylase, mTOR mammalian target of rapamycin, NOXA superoxide-generating NADPH oxidase, PAI1 plasminogen activator inhibitor 1, PANK1 pantothenate kinase 1, PDK PDH kinase, PIGs p53-induced gene, PML promyelocytic leukemia protein, PRL3 phosphatase of regenerating liver-3, PTPRV protein tyrosine phosphatase receptor type V, PUMA Bcl-2-binding component 3, ROS reactive oxygen species, RRM2 ribonucleoside-diphosphate reductase subunit M2, SAT1 spermine N1-acetyltransferase 1, SLC7A11 solute carrier family7 member11, TFR1 transferrin receptor 1, TIGAR TP53-induced glycolysis and apoptosis regulator, TP53INP1 tumor protein p53 inducible nuclear protein 1, XPC xeroderma pigmentosum group C protein, YAP1 yes-associated protein 1CC BY · PubMed Central
Fig. 3 Pro-tumor effect of p53. In general, p53 is thought to have tumor suppressive effects, but in some cases, p53 promotes tumor growth. In hepatocellular carcinoma cells, p53 transcription activates the expression of Puma, which causes shift in mitochondrial energy metabolism from oxidative phosphorylation to glycolysis, thereby promoting tumorigenesis. In hepatocyte-specific KRASG12D cells knockout of MDM2 to activate p53. Accumulated p53 increased inflammatory responses, hepatocyte apoptosis, and senescence-associated secretory phenotypes that promote carcinogenesis
Fig. 3 Pro-tumor effect of p53. In general, p53 is thought to have tumor suppressive effects, but in some cases, p53 promotes tumor growth. In hepatocellular carcinoma cells, p53 transcription activates the expression of Puma, which causes shift in mitochondrial energy metabolism from oxidative phosphorylation to glycolysis, thereby promoting tumorigenesis. In hepatocyte-specific KRASG12D cells knockout of MDM2 to activate p53. Accumulated p53 increased inflammatory responses, hepatocyte apoptosis, and senescence-associated secretory phenotypes that promote carcinogenesisCC BY · PubMed Central
Fig. 4 TP53 mutations in cancer. a Frequency of somatic TP53 mutations associated with different types of cancer. b Frequency of missense mutations in TP53 (https://tp53.isb-cgc.org/). c Mutation frequency of TP53 in different tissues and organs
Fig. 4 TP53 mutations in cancer. a Frequency of somatic TP53 mutations associated with different types of cancer. b Frequency of missense mutations in TP53 (https://tp53.isb-cgc.org/). c Mutation frequency of TP53 in different tissues and organsCC BY · PubMed Central
Fig. 5 The role of mutant p53 in cancer. Mutant p53 can result in loss-of-function of wild-type p53, dominant-negative repression of wild-type p53 by mutant p53, and gain-of-function with oncogenic properties. Mutant p53 affects various cellular responses, such as genomic instability, metabolic reprogramming, and tumor microenvironment, and promotes cancer cell proliferation, invasion, metastasis and drug resistance. WT wild-type
Fig. 5 The role of mutant p53 in cancer. Mutant p53 can result in loss-of-function of wild-type p53, dominant-negative repression of wild-type p53 by mutant p53, and gain-of-function with oncogenic properties. Mutant p53 affects various cellular responses, such as genomic instability, metabolic reprogramming, and tumor microenvironment, and promotes cancer cell proliferation, invasion, metastasis and drug resistance. WT wild-typeCC BY · PubMed Central
Fig. 6 TAD binds to partner proteins and regulates transcription. a MDM2/MDMX is the major negative regulator of p53, and the C-terminus of MDM2 has E3 ubiquitin ligase activity (Ub) that promotes p53 degradation. b Under cellular stress conditions, the acetyl group (Ac) is added to the lysine residue of p53-CTD, and p53 binds to the target DNA sequence and interacts with the coactivator CBP or p300 to jointly promote gene transcription. c DNA damage and other stresses induce p53 phosphorylation (P) and binding to TFIIH, which stabilizes p53 and promotes DNA binding and transcription. p53-TAD shown as cartoon. Partner proteins are shown as surfaces
Fig. 6 TAD binds to partner proteins and regulates transcription. a MDM2/MDMX is the major negative regulator of p53, and the C-terminus of MDM2 has E3 ubiquitin ligase activity (Ub) that promotes p53 degradation. b Under cellular stress conditions, the acetyl group (Ac) is added to the lysine residue of p53-CTD, and p53 binds to the target DNA sequence and interacts with the coactivator CBP or p300 to jointly promote gene transcription. c DNA damage and other stresses induce p53 phosphorylation (P) and binding to TFIIH, which stabilizes p53 and promotes DNA binding and transcription. p53-TAD shown as cartoon. Partner proteins are shown as surfacesCC BY · PubMed Central
Fig. 7 Structures of DBD, TET, CTD and full-length p53. a The structure of DBD in complex with a sequence-specific DNA (PDB: 1TSR). p53-DBD is shown as a cartoon, and the secondary structures are labeled. The interfacial residues are shown as sticks. DNA is shown as sticks and surfaces. b DNA recognition by the p53 tetramer (PDB: 3KMD). c ASPP2 (colored aquamarine). d iASPP (colored pale green). e 53BP1 (colored pink). f NMR structural model of the p53-DBD/BCL-xL complex. g Crystal structure of the p53-DBD/BCL-xL complex. BCL-xL is colored marine. h LTag (colored light blue). i E6/E6AP. E6 is colored light pink. E6AP is colored pale yellow. All p53-DBD molecules are shown as the surface. j Assembly of the p53 tetramerization domain (PDB: 1C26). k CTD sequence. The posttranscriptional modifications are shown as indicated. l A CTD peptide (colored light magenta) became a helical conformation when bound to Ca2+-loaded S100B(ββ) (colored pale cyan and pale green). m A CTD peptide dimethylated at K382 (p53K382me2) binds the tandem Tudor domain (TTD) of 53BP1 (colored yellow) in a U-shape conformation. n A p53 peptide acetylated at K381 and dimethylated at K382 (p53K381acK382me2) forms a helical conformation when interacting with 53BP1-TTD. o A p53K382ac peptide forms β sheet-like contacts with deacetylase Sir2-Af2 (colored light blue). p Structure of the p53/RNA polymerase II assembly. RNA polymerase II assembly is shown as surface. p53 is shown as cartoon. q Full-length p53 structure predicted by AlphaFold2. TAD colored pink, PRD colored green, DBD colored marine, Loop colored yellow, TET colored warm pink, and CTD colored cyan
Fig. 7 Structures of DBD, TET, CTD and full-length p53. a The structure of DBD in complex with a sequence-specific DNA (PDB: 1TSR). p53-DBD is shown as a cartoon, and the secondary structures are labeled. The interfacial residues are shown as sticks. DNA is shown as sticks and surfaces. b DNA recognition by the p53 tetramer (PDB: 3KMD). c ASPP2 (colored aquamarine). d iASPP (colored pale green). e 53BP1 (colored pink). f NMR structural model of the p53-DBD/BCL-xL complex. g Crystal structure of the p53-DBD/BCL-xL complex. BCL-xL is colored marine. h LTag (colored light blue). i E6/E6AP. E6 is colored light pink. E6AP is colored pale yellow. All p53-DBD molecules are shown as the surface. j Assembly of the p53 tetramerization domain (PDB: 1C26). k CTD sequence. The posttranscriptional modifications are shown as indicated. l A CTD peptide (colored light magenta) became a helical conformation when bound to Ca2+-loaded S100B(ββ) (colored pale cyan and pale green). m A CTD peptide dimethylated at K382 (p53K382me2) binds the tandem Tudor domain (TTD) of 53BP1 (colored yellow) in a U-shape conformation. n A p53 peptide acetylated at K381 and dimethylated at K382 (p53K381acK382me2) forms a helical conformation when interacting with 53BP1-TTD. o A p53K382ac peptide forms β sheet-like contacts with deacetylase Sir2-Af2 (colored light blue). p Structure of the p53/RNA polymerase II assembly. RNA polymerase II assembly is shown as surface. p53 is shown as cartoon. q Full-length p53 structure predicted by AlphaFold2. TAD colored pink, PRD colored green, DBD colored marine, Loop colored yellow, TET colored warm pink, and CTD colored cyanCC BY · PubMed Central
Fig. 8 Structure of MDM2/X with small molecules. a Overlay of the crystal structures of MDM2/p53-TAD (white, sky blue), MDMX/p53-TAD (greencyan, pink) and the three residues of p53-TAD (F19, W23, L26) are shown as sticks. b MDM2 is shown as a surface. c MDMX is shown as surface. d MDM2/RG7112 (PDB: 4IPF). e MDM2/RG7388 (PDB: 4JRG). f MDM2/AMG 232 (PDB: 4OAS). g MDM2/MI-77301 (PDB: 5TRF). h MDM2/NVP-CGM097 (PDB: 4ZYF). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored gray)
Fig. 8 Structure of MDM2/X with small molecules. a Overlay of the crystal structures of MDM2/p53-TAD (white, sky blue), MDMX/p53-TAD (greencyan, pink) and the three residues of p53-TAD (F19, W23, L26) are shown as sticks. b MDM2 is shown as a surface. c MDMX is shown as surface. d MDM2/RG7112 (PDB: 4IPF). e MDM2/RG7388 (PDB: 4JRG). f MDM2/AMG 232 (PDB: 4OAS). g MDM2/MI-77301 (PDB: 5TRF). h MDM2/NVP-CGM097 (PDB: 4ZYF). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored gray)CC BY · PubMed Central
Fig. 9 Compounds targeting cysteine in p53-DBD. a The amino acid sequence and structure of p53-DBD, cysteine is highlighted and labeled, p53 tetramers are labeled as (a–d), respectively and cysteines are shown as sticks. b MQ bound to C124, C229 and C277 in p53-R282W-DNA tetramers. The MQ conjugates are in stick representation (green). c Structure of p53-bound arsenic and zinc ions. d Structure of p53-bound antimony and zinc ions. The interacting amino acid residues are shown as sticks
Fig. 9 Compounds targeting cysteine in p53-DBD. a The amino acid sequence and structure of p53-DBD, cysteine is highlighted and labeled, p53 tetramers are labeled as (a–d), respectively and cysteines are shown as sticks. b MQ bound to C124, C229 and C277 in p53-R282W-DNA tetramers. The MQ conjugates are in stick representation (green). c Structure of p53-bound arsenic and zinc ions. d Structure of p53-bound antimony and zinc ions. The interacting amino acid residues are shown as sticksCC BY · PubMed Central
Fig. 10 Structure of the p53 mutant Y220C with small molecules. a p53-WT surface (PDB: 3KMD). b p53-Y220C surface (PDB: 2VUK). c p53-Y220C/Phikan083 (PDB: 2VUK). d p53-Y220C/Phikan5196 (PDB: 4AGQ). e p53-Y220C/PK7242 (PDB: 3ZME). f p53-Y220C/Compound9 (PDB: 5AOJ). g p53-Y220C/Compound6 (PDB: 5G4O). h p53-Y220C/MB710 (PDB: 5O1I). i p53-Y220C/PK9318 (PDB: 6GGB). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored greencyan)
Fig. 10 Structure of the p53 mutant Y220C with small molecules. a p53-WT surface (PDB: 3KMD). b p53-Y220C surface (PDB: 2VUK). c p53-Y220C/Phikan083 (PDB: 2VUK). d p53-Y220C/Phikan5196 (PDB: 4AGQ). e p53-Y220C/PK7242 (PDB: 3ZME). f p53-Y220C/Compound9 (PDB: 5AOJ). g p53-Y220C/Compound6 (PDB: 5G4O). h p53-Y220C/MB710 (PDB: 5O1I). i p53-Y220C/PK9318 (PDB: 6GGB). Water molecules are red spheres, and hydrogen bonds are black lines. The interacting amino acid residues are shown as sticks (colored greencyan)CC BY · PubMed Central
Fig. 11 Targeting p53 aggregation. p53-DBD has an amyloid-forming segment, LTIITLE, that forms Mutant p53 aggregates. ReAcp53, ADH-6 and LI inhibit p53 aggregation and restore the conformation and function of p53
Fig. 11 Targeting p53 aggregation. p53-DBD has an amyloid-forming segment, LTIITLE, that forms Mutant p53 aggregates. ReAcp53, ADH-6 and LI inhibit p53 aggregation and restore the conformation and function of p53CC BY · PubMed Central
Fig. 12 Antibody drugs against p53. a Structure of the Nb139/p53-DBD complex. p53-DBD shown as cartoon/surface (colored pink). Nb139 shown as cartoon (colored marine). b Mechanism of action and structure of the bispecific antibody H2-scDb. H2-scDb is a bispecific antibody that recognizes the p53R175H mutant peptide presented on the cell surface by HLA-A and binds to the T-cell receptor, activating T cells and releasing cytokines to kill tumor cells. The interacting amino acid residues are shown as sticks. Hydrogen bonds as black lines
Fig. 12 Antibody drugs against p53. a Structure of the Nb139/p53-DBD complex. p53-DBD shown as cartoon/surface (colored pink). Nb139 shown as cartoon (colored marine). b Mechanism of action and structure of the bispecific antibody H2-scDb. H2-scDb is a bispecific antibody that recognizes the p53R175H mutant peptide presented on the cell surface by HLA-A and binds to the T-cell receptor, activating T cells and releasing cytokines to kill tumor cells. The interacting amino acid residues are shown as sticks. Hydrogen bonds as black linesCC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 5 Not valid · 308 Not checked · 80 Own results and interpretations

196 more claims

Create a free account to see all 397 claims and to verify the 509 references still open.

See all claims — free account
  • It may state two separate claims as one. 173
  • Probably not a substantial claim. 36
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 586 references

Cited by

See all 1,016

Metadata

Authors
Wang, H., Guo, M., Wei, H., & Chen, Y.
Affiliations
Central South University (CN)
Corresponding author
  • Wei, Hudie
  • Chen, Yongheng
Venue
Signal Transduction and Targeted Therapy
Published
2023-03-01
Volume
8
Issue
1
Pages
92-92
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4322743974
Cited by
1,016
References
584
Citations by year
2026: 308 · 2025: 419 · 2024: 243 · 2023: 43
FWCI
32.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81570537, 81974074, 82172654, 82273496, 31900880)
  • Hunan Provincial Science and Technology Department (2018RS3026, 2021RC4012)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
TP53, p53, p53 pathway, TP53 mutation, p53-targeted therapy, tumor suppression, cellular metabolism, ferroptosis, tumor microenvironment, autophagy, apoptosis, cell cycle regulation, genome stability, anticancer drug development
MeSH terms
Ferroptosis, Autophagy, Cell Cycle, Humans, Tumor Suppressor Protein p53, Apoptosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting p53 pathways: mechanisms, structures, and advances in therapy. https://app.cochat.ai/papers/10.1038/s41392-023-01347-1
The paper
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023). Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01347-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.